Compare Cardinal Health Inc (CAH) vs STMicroelectronics NV (STM) Price & Performance

Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.

The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.

STM trades at $54.51, up 0.29% today, with a neutral technical signal and mixed earnings history. The stock shows a high P/E of 107.92 but benefits from strong cash flow and a solid balance sheet with $6.18B in cash. Recent news highlights AI data center growth potential, with management targeting over $2B in revenues by 2027, though Q3 2026 earnings expectations face scrutiny after past misses.

Outlook is cautiously optimistic with a consensus price target of $74.63, implying 37% upside, supported by 52% analyst buy ratings. Risks include execution challenges in AI initiatives, margin pressure from high capex, and sensitivity to semiconductor cycle downturns. Investor sentiment is balanced amid growth prospects and valuation concerns.